Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 18, 2003, Pages 3901-3911

  Piergentili, Alessandro ^a   Gentili, Francesco ^a   Ghelfi, Francesca ^a   Marucci, Gabriella ^a   Pigini, Maria ^a   Quaglia, Wilma ^a   Giannella, Mario ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,2 DIPHENYLETHYL) 5 METHYLTETRAHYDRO 1,3 DIOXOLO[4,5 C]PYRROLE OXALATE; 2 (2,2 DIPHENYLPROPYL) 5 METHYLTETRAHYDRO 1,3 DIOXOLO[4,5 C]PYRROLE OXALATE; 2 BENZHYDRYL 5 METHYLTETRAHYDRO 1,3 DIOXOLO[4,5 C]PYRROLE OXALATE; 2,2 DIPHENYL 1,3 DIOXOLAN 2 YLMETHYLDIMETHYLAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXALIC ACID DERIVATIVE; PIRENZEPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; PROTEIN PROTEIN INTERACTION; RABBIT; STEREOCHEMISTRY; VAS DEFERENS;

ORYCTOLAGUS CUNICULUS;

EID: 0041589307     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00431-0     Document Type: Article

References (57)

1. Broadley K.J., Kelly D.R. Molecules. 6:2001;142.
2. Felder C.C. FASEB J. 9:1995;619.
3. Hamilton S.E., Loose M.D., Qi M., Levey A.I., Hille B., McKnight G.S., Idzerda R.L., Nathanson N.M. Proc. Natl. Acad. Sci. U.S.A. 94:1997;13311.
4. Gomeza J., Shannon H., Kostenis E., Felder C.C., Zhang L., Brodkin J., Grinberg A., Sheng H., Wess J. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1692.
5. Matsui M., Motomura D., Karasawa H., Fujikawa T., Jiang J., Komiya Y., Takahashi S., Taketo M.M. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9579.
6. (a) Gomeza J., Zhang L., Kostenis E., Felder C.C., Bymaster F.P., Brodkin J., Shannon H., Xia B., Deng C., Wess J. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10483.
7. (b) Wess J., Duttaroy A., Gomeza J., Zhang W., Yamada M., Felder C.C., Bernardini N., Reeh P.W. Life Sci. 72:2003;2047.
8. Caulfield M.P. Pharmacol. Ther. 58:1993;319.
9. Ehlert F.J., Ostrom R.S., Sawyer G.W. Life Sci. 61:1997;1729.
10. Eglen R.M., Reddy H., Watson N., Challis R.A. Trends Pharmacol. Sci. 15:1994;114.
11. Lazareno S., Buckley N.J., Roberts F.F. Mol. Pharmacol. 38:1990;805.
12. Schulte B., Volz-Zang C., Mutschler E., Horne C., Palm D., Wellstein A., Pitschner H.F. Clin. Pharmacol. Ther. 50:1991;372.
13. Alabaster V.A. Life Sci. 60:1997;1053.
14. Oyasu H., Yamamoto T., Sato N., Sawada T., Ozaki R., Mukai T., Ozaki T., Nishii M., Sato H., Fujiwara T., Tozuka Z., Koibuchi Y., Honbo T., Esumi K., Ohtsuka M., Shimomura K. Arzneim.-Forsch./Drug Res. 44:1994;1242.
15. van Noord J.A., Bantje T.A., Eland M.E., Korducki L., Cornelissen P.J. Thorax. 55:2000;289.
16. Hammer R., Berrie C.P., Birdsall N.J.M., Burgen A.S.W., Hulme E.C. Nature. 283:1980;90.
17. Carmine A.A., Brogden R.N. Drugs. 30:1985;85.
18. Eglen R.M., Choppin A., Watson N. Trends Pharmacol. Sci. 22:2001;409.
19. Brann M.R., Jørgensen H.B., Burstein E.S., Spalding T.A., Ellis J., Jones S.V.P., Hill-Eubanks D. Ann. N. Y. Acad. Sci. 707:1993;225.
20. Hulme E.C., Birdsall N.J.M., Buckley N.J. Annu. Rev. Pharmacol. Toxicol. 30:1990;633.
21. Levey A.I. Life Sci. 52:1993;441.
22. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. J. Neurosci. 11:1991;3218.
23. Reever C.M., Ferrari Di Leo G., Flynn D.D. Life Sci. 60:1997;1105.
24. Felder C.C., Bymaster F.P., Ward J., DeLapp N. J. Med. Chem. 43:2000;4333.
25. Nochi S., Asakawa N., Sato T. Biol. Pharm. Bull. 18:1995;1145.
26. Bodick N.C., Offen W.W., Levey A.I., Cutler N.R., Gauthier S.G., Satlin A., Shannon H.E., Tollefson G.D., Rasmussen K., Bymaster F.P., Hurley D.J., Potter W.Z., Paul S.M. Arch. Neurol. 54:1997;465.
27. (a) Farlow M.R., Evans R.M. Neurology. 51:1998;S36.
28. (b) Quirion R., Wilson A., Rowe W., Aubert I., Richard J., Doods H., Parent A., White N., Meaney M.J. J. Neurosci. 15:1995;1455.
29. (c) Doods H.N. Drugs Future. 20:1995;157.
30. Quirion R., Aubert I., Lapchak P.A., Schaum R.P., Teolis S., Gauthier S., Araujo D.M. Trends Pharmacol. Sci. 10:1989;80.
31. (a) Stillman M.J., Shukitt-Hale B., Galli R.L., Levy A., Lieberman H.R. Brain Res. Bull. 41:1996;221.
32. (b) Billard W., Binch H., Crosby G., McQuade R.D. J. Pharmacol. Exp. Ther. 273:1995;273.
33. Olianas M.C., Onali P. Life Sci. 65:1999;2233.
34. Chang K.J., Deth R.C., Triggle D.J. J. Med. Chem. 15:1972;243.
35. Angeli P., Gulini U., Meloni M.T., Paparelli F., Quaglia W. Med. Chem. Res. 5:1995;271.
36. Piergentili A., Angeli P., Giannella M., Pigini M., Quaglia W., Tayebati S.K. Arzneim.-Forsch./Drug Res. 46:1996;99.
37. Gualtieri F., Romanelli M.N., Teodori E. Stud. Med. Chem. 1:1996;271.
38. Owen L.N. J. Chem. Soc. 1949;241.
39. Kuznetsov S.G., Libman N.M. Zh. Org. Khim. 1:1965;1399.
40. N'Goka V., Schlewer G., Linget J.-M., Chambon J.-P., Wermuth C.-G. J. Med. Chem. 34:1991;2547.
41. Neuhaus D., Williamson M.P. The Nuclear Overhauser Effect in Structural and Conformational Analysis. 1989;VCH, New York.
42. Taylor E.C., Chiang C.-S. Synthesis. 1977;467.
43. Takemura S., Miki Y., Uono M., Yoshimura K., Kuroda M., Suzuki A. Chem. Pharm. Bull. 29:1981;3026.
44. Kenakin T.P., Boselli C. Naunyn-Schmiedebergs Arch. Pharmacol. 344:1991;201.
45. Ringdahl B. Mol. Pharmacol. 31:1987;351.
46. Roffel A.F., Elzinga C.R.S., Zaagsma J. Eur. J. Pharmacol. 250:1993;267.
47. Eltze M. Eur. J. Pharmacol. 151:1988;205.
48. van Rossum J.M. Arch. Int. Pharmacodyn. Ther. 143:1963;299.
49. Arunlakshana O., Schild H.O. Br. J. Pharmacol. 14:1959;48.
50. Tallarida R.J., Cowan A., Adler M.W. Life Sci. 25:1979;637.
51. Eltze M., Figala V. Eur. J. Pharmacol. 158:1988;11.
52. Budriesi R., Cacciaguerra S., Di Toro R., Bolognesi M.L., Chiarini A., Minarini A., Rosini M., Spampinato S., Tumiatti V., Melchiorre C. Br. J. Pharmacol. 132:2001;1009.
53. Widzowski D., Helander H.F., Wu E.S.C. Drug Discov. Today. 2:1997;341.
54. Hypercube, Inc. HyperChem® for Windows, Release 5.0; Publication HC50-00-02-00, 419 Phillip St., Waterloo, Ontario, Canada, 1996.
55. Calculated logP (ClogP) values were computed by using the CS ChemDraw Ultra ver. 6.01, 15 September 2000; CambridgeSoft.Com: Cambridge, MA, USA.
56. Marino M.J., Rouse S.T., Levey A.I., Potter L.T., Conn P.J. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11465.
57. Yamada M., Miyakawa T., Duttaroy A., Yamanaka A., Moriguchi T., Makita R., Ogawa M., Chou C.J., Xia B., Crawley J.N., Felder C.C., Deng C.-X., Wess J. Nature. 410:2001;207.